{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:16:50Z","timestamp":1780413410525,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10537-8","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T18:31:54Z","timestamp":1750185114000},"page":"1167-1175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolving anticoagulation paradigms in left ventricular assist device (LVAD) patients: a focus on direct oral anticoagulants"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0073-4211","authenticated-orcid":false,"given":"Andrew","family":"Ndakotsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhvithi","family":"Pingili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Koskina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soad","family":"Al Osta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Feller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"1","key":"10537_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/icvts\/ivx255","volume":"26","author":"A McDavid","year":"2018","unstructured":"McDavid A, MacBrair K, Emani S et al (2018) Anticoagulation management following left ventricular assist device implantation is similar across all provider strategies. Interact Cardiovasc Thorac Surg 26(1):60\u201365. https:\/\/doi.org\/10.1093\/icvts\/ivx255","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"6","key":"10537_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.21037\/atm-20-4849","volume":"9","author":"RY Loyaga-Rendon","year":"2021","unstructured":"Loyaga-Rendon RY, Kazui T, Acharya D (2021) Antiplatelet and anticoagulation strategies for left ventricular assist devices. Ann Transl Med 9(6):521. https:\/\/doi.org\/10.21037\/atm-20-4849","journal-title":"Ann Transl Med"},{"issue":"10","key":"10537_CR3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/ejhf.2327","volume":"23","author":"T Ben Gal","year":"2021","unstructured":"Ben Gal T, Ben Avraham B, Milicic D et al (2021) Guidance on the management of left ventricular assist device (LVAD)-supported patients for the non-LVAD specialist healthcare provider: executive summary. Eur J Heart Fail 23(10):1597\u20131609. https:\/\/doi.org\/10.1002\/ejhf.2327","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10537_CR4","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMoa1900486","volume":"380","author":"MR Mehra","year":"2019","unstructured":"Mehra MR, Uriel N, Naka Y et al (2019) A fully magnetically levitated left ventricular assist device - final report. N Engl J Med 380(17):1618\u20131627. https:\/\/doi.org\/10.1056\/NEJMoa1900486","journal-title":"N Engl J Med"},{"issue":"4","key":"10537_CR5","doi-asserted-by":"publisher","DOI":"10.14503\/THIJ-23-8154","volume":"50","author":"E Yin","year":"2023","unstructured":"Yin E (2023) Pearls in anticoagulation management for patients with left ventricular assist devices. Tex Heart Inst J 50(4):e238154. https:\/\/doi.org\/10.14503\/THIJ-23-8154","journal-title":"Tex Heart Inst J"},{"issue":"7","key":"10537_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/aor.13116","volume":"42","author":"BK Martinez","year":"2018","unstructured":"Martinez BK, Yik B, Tran R et al (2018) Meta-analysis of time in therapeutic range in continuous-flow left ventricular assist device patients receiving warfarin. Artif Organs 42(7):700\u2013704. https:\/\/doi.org\/10.1111\/aor.13116","journal-title":"Artif Organs"},{"issue":"1","key":"10537_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jth.13902","volume":"16","author":"LM Baumann Kreuziger","year":"2018","unstructured":"Baumann Kreuziger LM, Kim B, Wieselthaler GM (2018) Antithrombotic therapy for mechanical circulatory support. J Thromb Haemost 16(1):1\u20139. https:\/\/doi.org\/10.1111\/jth.13902","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10537_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cardfail.2023.10.473","volume":"30","author":"M Dimond","year":"2024","unstructured":"Dimond M, Looby M, Shah B et al (2024) Design and rationale for the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study. J Card Fail 30(6):819\u2013828. https:\/\/doi.org\/10.1016\/j.cardfail.2023.10.473","journal-title":"J Card Fail"},{"issue":"23","key":"10537_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030380","volume":"12","author":"DS Lin","year":"2023","unstructured":"Lin DS, Lo HY, Huang KC et al (2023) Efficacy and safety of direct oral anticoagulants for stroke prevention in older patients with atrial fibrillation: a network meta-analysis of randomized controlled trials. J Am Heart Assoc 12(23):e030380. https:\/\/doi.org\/10.1161\/JAHA.123.030380","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10537_CR10","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1111\/aor.13848","volume":"45","author":"T Meredith","year":"2021","unstructured":"Meredith T, Schnegg B, Hayward C (2021) The use of direct oral anticoagulants in patients with ventricular assist devices: is there hope for factor Xa inhibition? Artif Organs 45(5):E123\u2013E129. https:\/\/doi.org\/10.1111\/aor.13848","journal-title":"Artif Organs"},{"issue":"18","key":"10537_CR11","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. Circulation 145(18):e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"issue":"25","key":"10537_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000000453","volume":"135","author":"S Maltais","year":"2017","unstructured":"Maltais S, Kilic A, Nathan S et al (2017) Management of anticoagulation for continuous-flow left ventricular assist devices: a scientific statement from the American Heart Association. Circulation 135(25):e1\u2013e42. https:\/\/doi.org\/10.1161\/CIR.0000000000000453","journal-title":"Circulation"},{"issue":"36","key":"10537_CR13","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"issue":"4","key":"10537_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6040103","volume":"6","author":"SA Kustos","year":"2019","unstructured":"Kustos SA, Fasinu PS (2019) Direct-acting oral anticoagulants and their reversal agents\u2014an update. Medicines (Basel) 6(4):103. https:\/\/doi.org\/10.3390\/medicines6040103","journal-title":"Medicines (Basel)"},{"issue":"4","key":"10537_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2478\/acph-2022-0034","volume":"72","author":"S Margeti\u0107","year":"2022","unstructured":"Margeti\u0107 S, Goreta S\u0160, \u0106elap I, Razum M (2022) Direct oral anticoagulants (DOACs): from the laboratory point of view. Acta Pharm 72(4):459\u2013482. https:\/\/doi.org\/10.2478\/acph-2022-0034","journal-title":"Acta Pharm"},{"issue":"4","key":"10537_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","volume":"72","author":"CJ Lee","year":"2011","unstructured":"Lee CJ, Ansell JE (2011) Direct thrombin inhibitors. Br J Clin Pharmacol 72(4):581\u2013592. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03916.x","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10537_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030757","volume":"11","author":"F Khalil","year":"2023","unstructured":"Khalil F, Asleh R, Perue RK et al (2023) Vascular function in continuous flow LVADs: implications for clinical practice. Biomedicines 11(3):757. https:\/\/doi.org\/10.3390\/biomedicines11030757","journal-title":"Biomedicines"},{"issue":"4","key":"10537_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/jcdd3040035","volume":"3","author":"M Capoccia","year":"2016","unstructured":"Capoccia M (2016) Mechanical circulatory support for advanced heart failure: are we about to witness a new \u201cgold standard\u201d? J Cardiovasc Dev Dis 3(4):35. https:\/\/doi.org\/10.3390\/jcdd3040035","journal-title":"J Cardiovasc Dev Dis"},{"issue":"4","key":"10537_CR19","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/aor.14456","volume":"47","author":"GA Giridharan","year":"2023","unstructured":"Giridharan GA, Berg IC, Ismail E et al (2023) Loss of pulsatility with continuous-flow left ventricular assist devices and the significance of the arterial endothelium in von-Willebrand factor production and degradation. Artif Organs 47(4):640\u2013648. https:\/\/doi.org\/10.1111\/aor.14456","journal-title":"Artif Organs"},{"issue":"3","key":"10537_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/0391398818806162","volume":"42","author":"M Selmi","year":"2019","unstructured":"Selmi M, Chiu WC, Chivukula VK et al (2019) Blood damage in left ventricular assist devices: pump thrombosis or system thrombosis? Int J Artif Organs 42(3):113\u2013124. https:\/\/doi.org\/10.1177\/0391398818806162","journal-title":"Int J Artif Organs"},{"issue":"25","key":"10537_CR21","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1182\/blood-2015-10-636480","volume":"127","author":"A Nascimbene","year":"2016","unstructured":"Nascimbene A, Neelamegham S, Frazier OH et al (2016) Acquired von Willebrand syndrome associated with left ventricular assist device. Blood 127(25):3133\u20133141. https:\/\/doi.org\/10.1182\/blood-2015-10-636480","journal-title":"Blood"},{"key":"10537_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.thromres.2015.11.002","volume":"137","author":"P Jilma-Stohlawetz","year":"2016","unstructured":"Jilma-Stohlawetz P, Quehenberger P, Schima H et al (2016) Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent. Thromb Res 137:196\u2013201. https:\/\/doi.org\/10.1016\/j.thromres.2015.11.002","journal-title":"Thromb Res"},{"issue":"1","key":"10537_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/joa.13675","volume":"242","author":"G Malone","year":"2023","unstructured":"Malone G, Abdelsayed G, Bligh F et al (2023) Advancements in left ventricular assist devices to prevent pump thrombosis and blood coagulopathy. J Anat 242(1):29\u201349. https:\/\/doi.org\/10.1111\/joa.13675","journal-title":"J Anat"},{"key":"10537_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.775780","volume":"9","author":"P Fang","year":"2022","unstructured":"Fang P, Du J, Boraschi A et al (2022) Insights into the low rate of in-pump thrombosis with the HeartMate 3: does the artificial pulse improve washout? Front Cardiovasc Med 9:775780. https:\/\/doi.org\/10.3389\/fcvm.2022.775780","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10537_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1313385","volume":"370","author":"RC Starling","year":"2014","unstructured":"Starling RC, Moazami N, Silvestry SC et al (2014) Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370(1):33\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1313385","journal-title":"N Engl J Med"},{"issue":"5","key":"10537_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/ejcts\/ezx020","volume":"51","author":"M Andreas","year":"2017","unstructured":"Andreas M, Wiedemann D, Haberl T et al (2017) Safety and efficacy of dabigatran in LVAD patients: a clinical perspective. Eur J Cardiothorac Surg 51(5):908\u2013912. https:\/\/doi.org\/10.1093\/ejcts\/ezx020","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4","key":"10537_CR27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.amjcard.2014.12.019","volume":"115","author":"JV Terrovitis","year":"2015","unstructured":"Terrovitis JV, Farmakis D, Katritsis DG et al (2015) The impact of dabigatran on anticoagulation outcomes in LVAD patients. Am J Cardiol 115(4):551\u2013555. https:\/\/doi.org\/10.1016\/j.amjcard.2014.12.019","journal-title":"Am J Cardiol"},{"issue":"11","key":"10537_CR28","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s11748-020-01371-w","volume":"68","author":"VY Parikh","year":"2020","unstructured":"Parikh VY, Parikh UM, Moctezuma-Ramirez A et al (2020) Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices. Gen Thorac Cardiovasc Surg 68(11):1278\u20131284. https:\/\/doi.org\/10.1007\/s11748-020-01371-w","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"3","key":"10537_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MAT.0000000000001650","volume":"68","author":"KR Whitehouse","year":"2022","unstructured":"Whitehouse KR, Avula D, Kahlon T et al (2022) Apixaban as alternative anticoagulation for HM3 LVAD. ASAIO J 68(3):355\u2013362","journal-title":"ASAIO J"},{"key":"10537_CR30","doi-asserted-by":"publisher","unstructured":"Soares C, Desai Y, Sorensen E, Dees L, Ananthram M, Hicks A (2024) Comparing Apixaban With Warfarin for Therapeutic Anticoagulation in Left Ventricular Assist Devices. Am J Cardiol 224:14\u201316. https:\/\/doi.org\/10.1016\/j.amjcard.2024.05.036","DOI":"10.1016\/j.amjcard.2024.05.036"},{"issue":"6","key":"10537_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.124.069726","volume":"150","author":"I Netuka","year":"2024","unstructured":"Netuka I, Tucanova Z, Ivak P et al (2024) A prospective randomized trial of direct oral anticoagulant therapy with a fully magnetically levitated LVAD: the DOT-HM3 Study. Circulation 150(6):509\u2013511. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069726","journal-title":"Circulation"},{"issue":"9","key":"10537_CR32","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.jchf.2024.04.013","volume":"12","author":"P Shah","year":"2024","unstructured":"Shah P, Looby M, Dimond M et al (2024) Evaluation of the hemocompatibility of the direct oral anticoagulant apixaban in left ventricular assist devices: the DOAC LVAD Study. JACC Heart Fail 12(9):1540\u20131549. https:\/\/doi.org\/10.1016\/j.jchf.2024.04.013","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10537_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.healun.2013.12.001","volume":"33","author":"SS Najjar","year":"2014","unstructured":"Najjar SS, Slaughter MS, Pagani FD et al (2014) An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 33(1):23\u201334. https:\/\/doi.org\/10.1016\/j.healun.2013.12.001","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"10537_CR34","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1161\/CIRCULATIONAHA.121.055716","volume":"144","author":"SM Cho","year":"2021","unstructured":"Cho SM, Mehaffey JH, Meyers SL et al (2021) Cerebrovascular events in patients with centrifugal-flow left ventricular assist devices: propensity score-matched analysis from the Intermacs registry. Circulation 144(10):763\u2013772. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055716","journal-title":"Circulation"},{"issue":"22","key":"10537_CR35","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1001\/jama.2023.23204","volume":"330","author":"MR Mehra","year":"2023","unstructured":"Mehra MR, Netuka I, Uriel N et al (2023) Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial. JAMA 330(22):2171\u20132181. https:\/\/doi.org\/10.1001\/jama.2023.23204","journal-title":"JAMA"},{"key":"10537_CR36","doi-asserted-by":"publisher","unstructured":"Shah\u202fP, Dimond\u202fM, Looby\u202fM, et\u202fal. (2024) Evaluation of the Hemocompatibility of the Direct Oral Anti\u2011Coagulant Apixaban in Left Ventricular Assist Devices (DOAC\u202fLVAD) Study. J\u202fCard Fail. 30(6):819\u2013828. https:\/\/doi.org\/10.1016\/j.cardfail.2023.10.473","DOI":"10.1016\/j.cardfail.2023.10.473"},{"key":"10537_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.amjcard.2024.11.026","volume":"238","author":"A Al-Abcha","year":"2024","unstructured":"Al-Abcha A, Clay S, Wang L et al (2024) Direct oral anticoagulants versus warfarin for the treatment of left ventricular thrombus: a multicenter retrospective observational study. Am J Cardiol 238:21\u201324. https:\/\/doi.org\/10.1016\/j.amjcard.2024.11.026","journal-title":"Am J Cardiol"},{"issue":"4","key":"10537_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1345\/aph.1A263","volume":"36","author":"TL Hawk","year":"2002","unstructured":"Hawk TL, Havrda DE (2002) Effect of stress on international normalized ratio during warfarin therapy. Ann Pharmacother 36(4):617\u2013620. https:\/\/doi.org\/10.1345\/aph.1A263","journal-title":"Ann Pharmacother"},{"issue":"14","key":"10537_CR39","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.040580","volume":"140","author":"EJ Dayoub","year":"2019","unstructured":"Dayoub EJ, Ross JS, Shah ND et al (2019) Evolution of Medicare formulary coverage changes for antithrombotic therapies after guideline updates. Circulation 140(14):1227\u20131230. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040580","journal-title":"Circulation"},{"key":"10537_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.849474","volume":"9","author":"JH Choi","year":"2022","unstructured":"Choi JH, Kim W, Kim YT et al (2022) Cost-effectiveness of direct oral anticoagulant vs. warfarin among atrial fibrillation patients with intermediate stroke risk. Front Cardiovasc Med. 9:849474. https:\/\/doi.org\/10.3389\/fcvm.2022.849474","journal-title":"Front Cardiovasc Med."},{"issue":"1","key":"10537_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.amjcard.2015.09.048","volume":"117","author":"BM Salata","year":"2016","unstructured":"Salata BM, Hutton DW, Levine DA et al (2016) Cost-effectiveness of dabigatran (150 mg twice daily) and warfarin in patients \u2265 65 years with nonvalvular atrial fibrillation. Am J Cardiol 117(1):54\u201360. https:\/\/doi.org\/10.1016\/j.amjcard.2015.09.048","journal-title":"Am J Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10537-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10537-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10537-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:03:28Z","timestamp":1763150608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10537-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10537"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10537-8","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"9 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants, animal subjects, or patient data, and therefore, ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}